Patents by Inventor Weimin Zhu

Weimin Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10494699
    Abstract: The invention provides a method of refining aluminum alloy, which is characterized in that aluminum-based nanometer quasicrystal alloy is used as an aluminum alloy refiner to refine the aluminum alloy; the aluminum-based nanometer quasicrystal alloy does not comprise Si, Fe or Cr; the aluminum-based nanometer quasicrystal alloy consists of (1) Al; (2) Mn and (3) La and/or Ce. The refiner selected in the invention is rare earth-containing alloy which has a strong refinement ability on the aluminum alloy, and is nanometer quasicrystal; after adding the rare earth-containing alloy to melt, the element distribution of the rare earth-containing alloy is more uniform than that of traditional alloy; and nanometer quasicrystal particles substantially increase the number of heterogeneous nucleation particles and improve the grain refinement effect of the aluminum alloy.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: December 3, 2019
    Assignees: CITIC DICASTAL CO., LTD., Hebei University of Technology
    Inventors: Lisheng Wang, Yongning Wang, Zhihua Zhu, Chunhai Liu, Changhai Li, Lateng A, Zhendong Zhang, Bangwei Bai, Weimin Zhao, Zhifeng Wang
  • Publication number: 20190309080
    Abstract: The present invention provides anti-RANKL monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
    Type: Application
    Filed: February 27, 2019
    Publication date: October 10, 2019
    Inventors: Yongke Zhang, Xiaodong Yang, Guo-Liang Yu, Weimin Zhu
  • Patent number: 10380223
    Abstract: A support tensor machine based neutral point grounding mode decision method and system adopts a support tensor machine method Based on three indexes, i.e., the power supply reliability index, safety index, and economical efficiency index, influences of different neutral point grounding modes are analyzed by employing the support tensor machine method to finally obtain a neutral point grounding mode capable of maximizing power supply reliability of a distribution network.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: August 13, 2019
    Assignees: STATE GRID ZHEJIANG ELECTRIC POWER COMPANY LIMITED, STATE GRID ZHEJIANG ECONOMIC RESEARCH INSTITUTE, STATE GRID NINGBO ELECTRIC POWER SUPPLY COMPANY LIMITED, ZHEJIANG HUAYUN ELECTRIC POWER ENGINEERING DESIGN CONSULTING CO. LTD
    Inventors: Yingjing He, Yangqing Dan, Weijun Liu, Weimin Zheng, Xiaodi Zhang, Chaoming Zheng, Xiran Wang, Shuyi Shen, Yan Yao, Yanwei Zhu, Fan Li, Lin Zhou, Jiandi Fang, Dan Yu, Ren Tang
  • Patent number: 10377814
    Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: August 13, 2019
    Assignee: EPITOMICS, INC.
    Inventors: Robert Pytela, Weimin Zhu, Yaohuang Ke, Qi Qian, Harry C. Au
  • Publication number: 20190212656
    Abstract: Methods for depositing an EUV hardmask film on a substrate by physical vapor deposition which allow for reduced EUV dose. Certain embodiments relate to metal oxide hardmasks which require smaller amounts of EUV energy for processing and allow for higher throughput. A silicon or metal target can be sputtered onto a substrate in the presence of an oxygen and or doping gas containing plasma.
    Type: Application
    Filed: January 10, 2019
    Publication date: July 11, 2019
    Inventors: Huixiong Dai, Weimin Zeng, Daniel Lee Diehl, Yong Cao, Hsiang Ning Wu, Khoi Phan, Christopher S. Ngai, Mingwei Zhu, Michael Stolfi, Nelson M. Felix, Ekmini Anuja DeSilva, Xianmin Tang
  • Patent number: 10259878
    Abstract: The present invention provides anti-RANKL monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: April 16, 2019
    Assignee: APEXIGEN, INC.
    Inventors: Yongke Zhang, Xiaodong Yang, Guo-Liang Yu, Weimin Zhu
  • Publication number: 20180369055
    Abstract: Disclosed is a postoperative functional exerciser for frozen shoulder. The exerciser includes a hand push rod (1) and a restrictive band (2) for restricting the elbow. The hand push rod (1) comprises a wristband (11) and a push rod (12). One end of the push rod (12) is connected with the wristband (11). When the hand push rod (1) and the restrictive band (2) are in operation, a part of the restrictive band (2) winds around the elbow joint of an affected arm, the other part winds around a waist buckle (3) at a waist portion of the restrictive band (2) on a side opposite to the affected arm, and the wristband (11) is sleeved on the wrist of the affected arm. The upper arm is tied to the body by means of the restrictive band (2).
    Type: Application
    Filed: August 31, 2018
    Publication date: December 27, 2018
    Inventors: Weimin ZHU, Daping WANG, Jianyi XIONG, Wei LU, Jiaming CUI, Kang CHEN, Liangquan PENG
  • Publication number: 20180273630
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: March 13, 2018
    Publication date: September 27, 2018
    Inventors: Yongke ZHANG, Guo-Liang Yu, Weimin Zhu
  • Publication number: 20180201900
    Abstract: Provided herein, inter alia, is a method for producing an enriched population of antigen-specific plasma cells. In some embodiments, the method may comprise: (a) obtaining a sample of cells from an animal that has been immunized by an antigen, wherein the sample comprises B cells; (b) enriching for a population of antigen-specific B cells that comprise cell surface antibodies that are specific for the antigen by: i. contacting at least 105 of the cells in said sample, en masse, with the antigen or a portion thereof; and ii. isolating cells that bind to the antigen or portion thereof; and (c) activating the enriched B cells, en masse, in the presence of the antigen or portion thereof, to produce the enriched population of antigen-specific plasma cells.
    Type: Application
    Filed: March 11, 2016
    Publication date: July 19, 2018
    Inventors: Luc Adam, Karin Vroom, Liang Xiang, Li Wei, Weimin Zhu
  • Patent number: 9994640
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: June 12, 2018
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Publication number: 20170246297
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: May 12, 2017
    Publication date: August 31, 2017
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Publication number: 20170233483
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: December 19, 2016
    Publication date: August 17, 2017
    Inventors: Yongke ZHANG, Guo-Liang YU, Weimin ZHU
  • Patent number: 9676861
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: June 13, 2017
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Patent number: 9556278
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: January 31, 2017
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Patent number: 9441042
    Abstract: The present invention provides anti-KDR monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of cancers, rheumatoid arthritis, diabetic retinopathy and other diseases associated with aberrant VEGF or KDR expression and/or activity.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: September 13, 2016
    Assignee: Apexigen, Inc.
    Inventors: Yaohuang Ke, Sum Wai Pierre Lee, Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Publication number: 20160207982
    Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.
    Type: Application
    Filed: April 1, 2016
    Publication date: July 21, 2016
    Inventors: Robert Pytela, Weimin Zhu, Yaohuang Ke, Qian Qi, Harry C. Au
  • Publication number: 20160208007
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: January 14, 2016
    Publication date: July 21, 2016
    Inventors: Yongke ZHANG, Guo-Liang Yu, Weimin Zhu
  • Patent number: D848396
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: May 14, 2019
    Assignee: Honeywell International Inc.
    Inventors: May Wilson, Jie Zhu, Weimin Zhou, Claes Haglund, Erik Pertot, Trym Holter
  • Patent number: D848679
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: May 14, 2019
    Assignee: Honeywell International Inc.
    Inventors: May Wilson, Weimin Zhou, Jie Zhu
  • Patent number: D856594
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: August 13, 2019
    Assignee: HONEYWELL INTERNATIONAL INC.
    Inventors: May Wilson, Jie Zhu, Weimin Zhou